Major HIV breakthrough forces hidden fragments of the virus to emerge so it can be cleared from the body
Researchers in Australia has developed a new treatment that forces hidden fragments of the virus - normally concealed within human cells - to emerge and expose themselves to the immune system.
The breakthrough could enable the body, aided by antiviral drugs, to detect and destroy any lingering viral reservoirs.
HIV has remained incurable because the virus can integrate itself into a cell's DNA, laying dormant and undetectable to both medication and immune defenses.
Scientists said they've created a nanoparticle capable of delivering genetic instructions to infected cells, prompting them to produce a signal that reveals the virus's presence.
Dr Paula Cevaal of the Doherty Institute and co-author of the study told The Guardian that the feat was 'previously thought impossible'.
Cevaal said: 'In the field of biomedicine, many things eventually don't make it into the clinic, that is the unfortunate truth; I don't want to paint a prettier picture than what is the reality.
'But in terms of specifically the field of HIV cure, we have never seen anything close to as good as what we are seeing, in terms of how well we are able to reveal this virus.
'So, from that point of view, we're very hopeful that we are also able to see this type of response in an animal, and that we could eventually do this in humans.'
The discovery was first revealed in the journal Nature Communications, where researchers said they were initially so astonished that they had to rerun the tests.
Further research would be needed to determine whether revealing the virus would be enough to trigger an immune response, with tests only being carried out in the lab.
It could still take years before clinical trials for the drug began, when it would have to go through rigorous testing before reaching consumers.
However, the advance represents another step forward for the 1.2 million Americans currently living with an HIV infection - for which they took drugs daily.
An estimated 31,800 people were believed to be infected every year, although that's a 12 per cent decline on five years ago.
Globally, nearly 40 million people have the virus.
The new nanoparticle's based on mRNA technology, the same as was used in covid vaccines made by Pfizer and other vaccine manufacturers.
In their paper, the scientists revealed that they could deliver mRNA instructions to cells using the nanoparticle. The mRNA then instruct cells to generate substances that reveal the presence of HIV, but only if the virus was present.
The study done in the laboratory was carried out in cells donated by HIV patients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
2 hours ago
- The Independent
Millions of people are suffering from brain fog. A new study will find out why
Millions of people who recover from infections like COVID-19, influenza and glandular fever are affected by long-lasting symptoms. These include chronic fatigue, brain fog, exercise intolerance, dizziness, muscle or joint pain and gut problems. And many of these symptoms worsen after exercise, a phenomenon known as post-exertional malaise. Medically the symptoms are known as myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS). The World Health Organization classifies this as a post viral fatigue syndrome, and it is recognised by both the WHO and the United States Centers for Disease Control and Prevention as a brain disorder. Experiencing illness long after contracting an infection is not new, as patients have reported these symptoms for decades. But COVID-19 has amplified the problem worldwide. Nearly half of people with ongoing post-COVID symptoms – a condition known as long-COVID – now meet the criteria for ME/CFS. Since the start of the pandemic in 2020, it is estimated that more than 400 million people have developed long-COVID. To date, no widely accepted and testable mechanism has fully explained the biological processes underlying long-COVID and ME/CFS. Our work offers a new perspective that may help close this gap. Our research group studies blood and the cardiovascular system in inflammatory diseases, as well as post-viral conditions. We focus on coagulation, inflammation and endothelial cells. Endothelial cells make up the inner layer of blood vessels and serve many important functions, like regulating blood clotting, blood vessel dilation and constriction, and inflammation. Our latest review aims to explain how ME/CFS and long-COVID start and progress, and how symptoms show up in the body and its systems. By pinpointing and explaining the underlying disease mechanisms, we can pave the way for better clinical tools to diagnose and treat people living with ME/CFS and long-COVID. What is endothelial senescence? In our review, our international team proposes that certain viruses drive endothelial cells into a half-alive, 'zombie-like' state called cellular senescence. Senescent endothelial cells stop dividing, but continue to release molecules that awaken and confuse the immune system. This prompts the blood to form clots and, at the same time, prevent clot breakdown, which could lead to the constriction of blood vessels and limited blood flow. By placing 'zombie' blood-vessel cells at the centre of these post-viral diseases, our hypothesis weaves together microclots, oxygen debt (the extra oxygen your body needs after strenuous exercise to restore balance), brain-fog, dizziness, gut leakiness (a digestive condition where the intestinal lining allows toxins into the bloodstream) and immune dysfunction into a single, testable narrative. From acute viral infection to 'zombie' vessels Viruses like SARS-CoV-2, Epstein–Barr virus, HHV-6, influenza A, and enteroviruses (a group of viruses that cause a number of infectious illnesses which are usually mild) can all infect endothelial cells. They enable a direct attack on the cells that line the inside of blood vessels. Some of these viruses have been shown to trigger endothelial senescence. Multiple studies show that SARS-CoV-2 (the virus which causes COVID-19 disease) has the ability to induce senescence in a variety of cell types, including endothelial cells. Viral proteins from SARS-CoV-2, for example, sabotage DNA-repair pathways and push the host cell towards a senescent state, while senescent cells in turn become even more susceptible to viral entry. This reciprocity helps explain why different pathogens can result in the same chronic illness. Influenza A, too, has shown the ability to drive endothelial cells into a senescent, zombie-like state. What we think is happening We propose that when blood-vessel cells turn into 'zombies', they pump out substances that make blood thicker and prone to forming tiny clots. These clots slow down circulation, so less oxygen reaches muscles and organs. This is one reason people feel drained. During exercise, the problem worsens. Instead of the vessels relaxing to allow adequate bloodflow, they tighten further. This means that muscles are starved of oxygen and patients experience a crash the day after exercise. In the brain, the same faulty cells let blood flow drop and leak, bringing on brain fog and dizziness. In the gut, they weaken the lining, allowing bits of bacteria to slip into the bloodstream and trigger more inflammation. Because blood vessels reach every corner of the body, even scattered patches of these 'zombie' cells found in the blood vessels can create the mix of symptoms seen in long-COVID and ME/CFS. Immune exhaustion locks in the damage Some parts of the immune system kill senescent cells. They are natural-killer cells, macrophages and complement proteins, which are immune molecules capable of tagging and killing pathogens. But long-COVID and ME/CFS frequently have impaired natural-killer cell function, sluggish macrophages and complement dysfunction. Senescent endothelial cells may also send out a chemical signal to repel immune attack. So the 'zombie cells' actively evade the immune system. This creates a self-sustaining loop of vascular and immune dysfunction, where senescent endothelial cells persist. In a healthy person with an optimally functioning immune system, these senescent endothelial cells will normally be cleared. But there is significant immune dysfunction in ME/CFS and long-COVID, and this may enable the 'zombie cells' to survive and the disease to progress. Where the research goes next There is a registered clinical trial in the US that is investigating senescence in long-COVID. Our consortium is testing new ways to spot signs of ageing in the cells that line our blood vessels. First, we expose healthy endothelial cells in the lab to blood from patients to see whether it pushes the cells into a senescent, or 'zombie,' state. At the same time, we are trialling non‑invasive imaging and fluorescent probes that could one day reveal these ageing cells inside the body. In selected cases, tissue biopsies may later confirm what the scans show. Together, these approaches aim to pinpoint how substances circulating in the blood drive cellular ageing and how that, in turn, fuels disease. Our aim is simple: find these ageing endothelial cells in real patients. Pinpointing them will inform the next round of clinical trials and open the door to therapies that target senescent cells directly, offering a route to healthier blood vessels and, ultimately, lighter disease loads.
The Guardian
3 hours ago
- The Guardian
‘Changed my life': hepatitis treatment offers hope but not enough receiving care, report finds
In 1989 David Clune was a young dad with four children when he was diagnosed with hepatitis B and C. Being told he wouldn't get to see them grow up 'was like a spear went through my heart', he remembers. Clune is not sure how he contracted the virus. However, entering state care in New Zealand at the age of 10, he experienced abuse and neglect as he was cycled through eight different homes, three youth detention centres, one adult remand centre and a psychiatric hospital, and was exposed to shared needles for tattooing and drugs. Clune quit drugs when he was 17 after meeting his long-term partner Grace and focused on their young family and working in a farming community. But life in the community became untenable after the stigma of Clune's diagnosis came at the same time as the Aids epidemic. 'They didn't have the understanding as they do now. It was that horrific that the children that used to play with my children in the community were no longer allowed to.' Clune progressively became sicker. 'I was a dying young dad – my organs were all failing, my kidney, my liver, my heart was under stress, everything. I was in really bad shape.' Sign up: AU Breaking News email In 1992, in the face of stigma, Clune's family emigrated to Brisbane with only $180. When he got to Australia his doctor referred him to the hepatology unit at Princess Alexandria hospital. 'Those guys changed my life,' he says. 'They knew what I'd been through and they built my trust. And when they built my trust, they built my health.' Clune is among the 300,000 people in Australia who live with hepatitis B and hepatitis C – viruses that affect the liver and which, without treatment, can lead to liver disease and liver cancer. For Clune and others, life has become significantly better now there is a cure for hepatitis C and treatment for hepatitis B, but a new report shows many people aren't receiving this care because they don't realise they are at risk or are disconnected from care. Released by Hepatitis Australia on Monday, it shows how hepatitis of all types is distributed among a typical 100 people affected. It concludes that 69 of those 100 people are living with hepatitis B, which is overwhelmingly the most prevalent blood-borne virus in Australia. The remaining 24 are living with hepatitis C, four are living with both hepatitis B and D, and three are living with hepatitis B and hepatitis C. However, only one in three people living with hepatitis B know they have it, and more than half are not receiving the care they need to appropriately monitor their liver health and viral load, and determine if and when antiviral treatment should commence, the report found. Most people (70 out of 100) with hepatitis B were born overseas, according to the report, titled 'If hepatitis was 100 people'. Sign up to Breaking News Australia Get the most important news as it breaks after newsletter promotion 'While people born in Australia since the year 2000 (when hepatitis B vaccinations began being routinely offered) are protected, people born before then, or those born overseas could be living with the virus and not know it because the symptoms often aren't obvious until the liver is severely damaged,' Lucy Clynes, the chief executive of Hepatitis Australia, said. The number of people living with hepatitis C has more than halved since 2016 when unrestricted access to direct-acting antiviral cures became available, but the uptake of the cure has declined 'significantly' since then, the report found. Stigma and discrimination associated with injecting drug use remains a barrier for all people living with hepatitis C in accessing treatment, the report stated. Out of 100 people with hepatitis C, 84 no longer inject drugs or contracted the disease in other ways. Clynes said the work to ensure people who inject drugs are receiving the cure has been effective, 'which is why we're seeing a change in the population'. The people who contracted hepatitis C in other ways – which could be unsafe tattooing, receiving a blood transfusion before 1990 (when screening was introduced) or getting a medical or dental procedure in a country with poor blood safety regulations, are less likely to be interacting with medical services, Clynes said. The report says population-wide testing should be carried out urgently, along with targeted education, and culturally safe care pathways – otherwise Australia will not meet its commitment to eliminate viral hepatitis by 2030, in line with global WHO targets.
The Guardian
3 hours ago
- The Guardian
‘We want women to have role models': how Sydney University is enticing more female academics to engineering
When Dr Jacqueline Thomas started her academic career in civil engineering a decade ago, she was one of just two full-time women in the school. Thomas had returned to Australia after a stint in Africa to teach a new humanitarian engineering major at the University of Sydney, the first of its kind in the country. 'It was crazy, it really took me by surprise,' she said. 'When I started, I just thought, 'great, I got the job, perfect'. And then I realised.' In 2025 the percentage of female academics at the faculty is still languishing below 20%. Hoping to correct systemic gender inequities facing the sector, the University of Sydney has launched its first engineering faculty recruitment drive to offer academic roles reserved for women. Five schools are part of the campaign, including aerospace, mechanical and mechatronic engineering, civil engineering, computer science, and electrical and computer engineering, where between 12% and 17% of continuing academic staff are female. Thomas, who has recently given birth to her second child, said 'the greater diversity that we have within our teaching space demonstrates for our student cohort that these pathways are possible'. 'I think that's really important, especially as I'm a mum. It hasn't always been easy, and there's definitely been moments where you have doubts … but I think it is important for female students to see those examples,' she said. Sign up: AU Breaking News email Prof Renae Ryan, a biomedical engineer at Sydney University who helmed the initiative, says it is one of the largest recruitment campaigns for women in the industry's history. 'We want to reflect the society we serve,' she said. 'If you're looking at universities and you go to information nights and there's no women, you feel like an outsider. We want women to have role models and people that they can look up to and see themselves as engineers.' Ryan, who is the associate dean of culture and community in the faculty of engineering, has been in the industry for more than two decades. She was previously the academic director of the university's Science in Australia Gender Equity program. She said that in medicine and biology, courses now often comprised 50% or more women at junior levels before dropping off at later study stages, but in engineering, numbers had been low 'the whole way through'. 'When you're the minority, in any industry, it can feel very isolating and lonely,' she said. 'Women can feel undervalued and disrespected at times as well, particularly in engineering and the automotive industry. 'You've just got additional barriers all the time to get over, and you don't have the same opportunities as other people. You get overlooked.' A Diversity Council Australia report released last year found just 11% of engineering students who identify as female go on to work in an engineering role, and of those, just 4% were born in Australia. Sign up to Breaking News Australia Get the most important news as it breaks after newsletter promotion The gender pay gap for women in engineering was 24% compared with 14% across all industries. Ryan said the barriers began early on. Girls selected out of maths and science subjects, she said, even if they were good at them, due to 'societal pressures and cultural norms'. But she said the idea men and women have different skill sets lending themselves to certain careers was 'garbage'. 'There are some countries where the engineering workforce is actually more female dominated,' she said, pointing to Turkey, Iran and Egypt, where women constitute a significant and growing portion of the engineering workforce. The implications of gender equity in the workforce aren't just good optics, either. The history of invention is one in which our world has catered to the male body. For instance, women are more likely to be moderately or seriously injured in car crashes, even when controlling for external factors like crash intensity, because vehicles were designed for men. Cars were modelled off car crash test dummies based on the 'average' male and seatbelts were also fitted with a male body type in mind, which can not only lead to discomfort but serious safety concerns. 'We need women in the engineering workforce … because if we don't have diversity in the people doing the work and designing these systems, we're not getting the best out of the technology,' Ryan said. 'We're not building it for everyone. We're building it for select groups.'
